Randox at AACC 2018 - Booth #3624

Location : McCormick Place, Chicago, Illinois
  Date : July 31st - August 2nd 2018

Evidence Series


Evidence series immunoassay analyzers guarantee cost-effective, highly accurate and flexible testing solutions. Having been developed to work with patented Biochip Array Technology, this precision multiplex testing platform allows for the simultaneous quantitative or qualitative detection of a wide range of analytes from a single sample.

This multiplex system delivers an unrivaled increase in patient information, offering a more in-depth diagnostic profile with each patient sample. This further analysis places the focus on the diagnosis, and on improving patient outcomes.





  • Fully automated immunoanalyzer
  • Throughput of up to 2640 tests per hour
  • Up to 44 analytes screened per biochip
  • Continuous sample, reagent and biochip input and output
  • True walkaway time of 2 hours
  • Revolutionary Reflex Testing
  • State of the art intuitive e-touch software
  • Advanced precision bio-drive robotics
  • 1.32m (H) x 1.2m (D) x 1.68m (W)



  • World’s first Biochip Array Technology (BAT) system
  • Fully automated analyser immunoanalyzer
  • Throughput of up to 3960 tests per hour
  • Sample capacity of 180
  • Up to 44 analytes screened per biochip
  • Dedicated software to control all on-board system operations
  • 1.7m (H) x 1m (D) x 2m (W)

 Evidence Investigator


  • Semi-automated benchtop immunoanalyzer
  • up to 2376 tests per hour
  • Up to 44 analytes screened per biochip
  • Suitable for medium throughput laboratories
  • Extremely robust with only one moving part
  • 0.75m (H) x 0.48m (D) x 0.42m (W)



  • Fully automated benchtop immunoanalyzer
  • Up to 132 tests per hour
  • Results generated in 17 minutes
  • Up to 44 analytes screened per biochip
  • 3 steps from sample entry to results
  • No laboratory / laboratory experience required to operate
  • Suitable for use in a range of laboratory and non-laboratory settings
  • 0.59m (H) x 0.54m (D) x 0.57m (W)


Revolutionary methodology free from Biotin-Streptavidin

The recent increase in popularity of biotin containing supplements to promote healthy hair, skin and nails has led to major concerns relating to its potential impact on diagnostic test results. Many immunoassay tests utilize the biotin-streptavidin method, where microparticles coated with streptavidin capture biotin which in turn is attached to the target antibody. The problem arises when excess biotin in the patient sample interferes with the streptavidin coated microparticles ability to capture the target analyte, leading to falsely elevated or falsely lowered results and ultimately misdiagnosis.

However, Randox Laboratories have the solution.

Our revolutionary Biochip Array Technology from Randox does not employ the biotin-streptavidin method, increasing confidence in your laboratory’s immunoassay test results.

Biochip Array Technology enables the simultaneous/multiplex detection of a wide range of analytes from a single patient sample ultimately producing a complete patient profile for more informed diagnosis. Additional benefits include:

  • Excellent correlation to gold standard methods
  • Reduced costs and time owing to the multiplex nature of the method
  • Small sample volume
  • Multiple sample matrices